Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 1;113(3):234-243.
doi: 10.1093/jnci/djaa064.

Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research

Toni K Choueiri  1 , Michael B Atkins  2 , Ziad Bakouny  1 , Maria I Carlo  3 , Charles G Drake  4 , Eric Jonasch  5 , Payal Kapur  6 , Bryan Lewis  7 , W Marston Linehan  8 , Michael J Mitchell  9 , Sumanta K Pal  10 , Kevin Pels  1 , Susan Poteat  7 , W Kimryn Rathmell  11 , Brian I Rini  11 , Sabina Signoretti  1   12 , Nizar Tannir  5 , Robert Uzzo  13 , Christopher G Wood  14 , Hans J Hammers  6
Affiliations

Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research

Toni K Choueiri et al. J Natl Cancer Inst. .

Abstract

Kidney cancer is one of the 10 most common cancers both in the United States and worldwide. Until this year, there had not previously been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. Therefore, a group of researchers, clinicians, and patient advocates dedicated to renal cell carcinoma launched the Kidney Cancer Research Summit (KCRS) to spur collaboration and further therapeutic advances in these tumors. This commentary aims to summarize the oral presentations and serve as a record for future iterations of this meeting. The KCRS sessions addressed the tumor microenvironment, novel methods of drug delivery, single cell sequencing strategies, novel immune checkpoint blockade and cellular therapies, predictive biomarkers, and rare variants of kidney cancers. In addition, the meeting included 2 sessions to promote scientific mentoring and kidney cancer research collaborations. A subsequent KCRS will be planned for the fall of 2020.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Challenges and controversies facing the renal cell carcinoma (RCC) research and clinical communities.
Figure 2.
Figure 2.
Subject areas covered in oral presentations at the Kidney Cancer Research Summit (KCRS) 2019. CAR-T = chimeric antigen receptor T; HERV-E = human endogenous retrovirus type E; MMP = matrix metalloprotease; PARP = poly(ADP-ribose) polymerase.
See this image and copyright information in PMC

References

    1. Gupta AK, Coburn JM, Davis-Knowlton J, Kimmerling E, Kaplan DL, Oxburgh L.. Scaffolding kidney organoids on silk. J Tissue Eng Regen Med. 2019;13(5):812–822. - PMC - PubMed
    1. Knezevic CE, Wright G, Remsing Rix LL, et al.. Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets. Cell Chem Biol. 2016;23(12):1490–1503. - PMC - PubMed
    1. Thomas C, Ji Y, Lodhi N, et al.. Non-NAD-Like poly(ADP-Ribose) polymerase-1 inhibitors effectively eliminate cancer in vivo. EBioMedicine. 2016;13:90–98. - PMC - PubMed
    1. Fahey CC, Davis IJ.. Setting the stage for cancer development: SETD2 and the consequences of lost methylation. Cold Spring Harb Perspect Med. 2017;7(5):a026468–16. - PMC - PubMed
    1. Park IY, Powell RT, Tripathi DN, et al.. Dual chromatin and cytoskeletal remodeling by SETD2. Cell. 2016;166(4):950–962. - PMC - PubMed

Publication types